Clinical Trial

Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

Study acronym: LC_Biomarker
Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Protocol Amendment History 4 changes
notable Enrollment increased: 800 -> 2000 participants 2026-08-13
notable Sponsor changed: Se-Hoon Lee -> Samsung Medical Center 2026-08-13
notable Primary completion pushed: 2020-12-31 -> 2030-12-31 2026-08-13
minor Completion pushed: 2025-12-31 -> 2030-12-31 2026-08-13
Trial Details
NCT Number NCT03578185
Lead Sponsor Samsung Medical Center
Conditions Lung Cancer
Enrollment 2,000 participants
Start Date 2018-04-11
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12